Publication Name	World Journal of Virology
Manuscript ID	65550
Country	United Kingdom

Received	2021-03-09 18:34
Peer-Review Started	2021-03-09 18:41
To Make the First Decision
Return for Revision	2021-04-06 16:57
Revised	2021-04-08 17:38
Second Decision	2021-04-26 09:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-04-26 11:40
Articles in Press	2021-04-26 11:40
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-05-15 07:02
Publish the Manuscript Online	2021-05-18 11:27

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Impact of COVID-19 in patients with lymphoid malignancies
Manuscript Source	Invited Manuscript
All Author List	John Charles Riches
ORCID	Author(s) ORCID Number John Charles Riches http://orcid.org/0000-0002-3425-7686
Funding Agency and Grant Number
Corresponding Author	John Charles Riches, BM BCh, MA, MRCP, N/A, PhD, N/A, N/A, Centre for Haemato-Oncology, Barts Cancer Institute – a Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, 3rd Floor John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. j.riches@qmul.ac.uk
Key Words	COVID-19; Lymphoma; Leukemia; Chemoimmunotherapy; Hemopoietic stem cell transplantation; Vaccination
Core Tip	Patients with lymphoid malignancies who have coronavirus disease 2019 (COVID-19) severely enough to require hospital assessment have an approximately one-third chance of dying from the infection, representing a slightly greater than 2-fold increased risk compared to the general population. Despite initial concerns, treatment for lymphoma is not associated with increased risk for poor outcome. Current evidence for the efficacy of COVID-19 vaccines in patients with lymphoid malignancies is extremely limited, so it will be crucial to conduct studies to address this issue over the coming months.
Publish Date	2021-05-18 11:27
Citation	Riches JC. Impact of COVID-19 in patients with lymphoid malignancies. World J Virol 2021; 10(3): 97-110
URL	https://www.wjgnet.com/2220-3249/full/v10/i3/97.htm
DOI	https://dx.doi.org/10.5501/wjv.v10.i3.97

Full Article (PDF)	WJV-10-97.pdf
Full Article (Word)	WJV-10-97.docx
Manuscript File	65550_Auto_Edited-ZMG.docx
Answering Reviewers	65550-Answering reviewers.pdf
Audio Core Tip	65550-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	65550-Conflict-of-interest statement.pdf
Copyright License Agreement	65550-Copyright license agreement.pdf
Peer-review Report	65550-Peer-review(s).pdf
Scientific Misconduct Check	65550-Scientific misconduct check.pdf
Scientific Editor Work List	65550-Scientific editor work list.pdf
CrossCheck Report	65550-CrossCheck report.pdf